Affinia Therapeutics
Waltham, US · Founded 2019 · Delaware corporation · 8 known investors
Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions. The company uses AI and structural modeling to redesign viral delivery vectors for one-time-dose genetic medicines across rare and prevalent diseases.
AI & Machine LearningBiotechDeep Tech
Founders & leadership
Affinia Therapeutics was founded in 2019 by Luc Vandenberghe.
LV
Luc VandenbergheFounder
RD
Rami DaoudExecutive
RM
Rick ModiChief Executive Officer, Board Member
LR
Laura RichmanExecutive
PK
Petra KaufmannExecutive
RA
Robert AboudExecutive
PC
Paula CobbExecutive
RM
Rob MayExecutive
CA
Charles AlbrightExecutive
AT
Aaron Tward, M.D., Ph.D.Scientific Co-Founder
BR
Botond Roska, M.D., Ph.D.Scientific Co-Founder
LV
Luk Vandenberghe, Ph.D.Scientific Co-Founder and Adviser, and Board Member
Investors · 8
Atlas VentureCambridge · $500K – $1M
EcoR1 CapitalSan Francisco
Eight Roads VenturesMumbai · $5M – $30M
F-Prime CapitalCambridge · $3M – $10Mvia Robert Weisskoff · board
GV (Google Ventures)Mountain View · $250K – $50M
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
TCG CrossoverPalo Alto
NEA SecondaryreportedTimonium
Reported raises · per SEC filings
Form D private placements$170.1M disclosed across 4 rounds · 2019–2025
▶$13.3MraisedOct 2025 · 20 investors · OtherRule 506(b)
▶$13.3MraisedOct 2025 · 20 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Carole FaigDirector
- Rami DaoudExecutive Officer
- Robert WeisskoffDirector
- Diana BrainardDirector
- Rick ModiExecutive Officer, Director
- David GrayzelDirector
- Luc VandenbergheDirector
- Elliott SigalDirector
- Edward MathersDirector
- Sean NolanDirector
- Offering amount
- $45M
- Amount sold
- $13.3M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$110MraisedMay 2021 · 22 investors · OtherRule 506(b)
▶$110MraisedMay 2021 · 22 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Laura RichmanExecutive Officer
- Rick ModiExecutive Officer, Director
- Petra KaufmannExecutive Officer
- Robert AboudExecutive Officer
- Paula CobbExecutive Officer
- Edward MathersDirector
- Sean NolanDirector
- Caroline StoutDirector
- Elliot SigalDirector
- Rob MayExecutive Officer
- Charles AlbrightExecutive Officer
- Luc VandenbergheDirector
- Robert WeisskoffDirector
- David GrayzelDirector
- Offering amount
- $110M
- Amount sold
- $110M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$38.5MraisedMar 2020 · 16 investors · OtherRule 506(b)
▶$38.5MraisedMar 2020 · 16 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Robert AboudExecutive Officer
- Robert JohnsonExecutive Officer
- Sean NolanDirector
- Luc VandenbergheDirector
- Rick ModiExecutive Officer, Director
- David GrayzelDirector
- Robert WeisskoffDirector
- Edward MathersDirector
- Offering amount
- $68.5M
- Amount sold
- $38.5M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$8.3MraisedNov 2019 · 14 investors · OtherRule 506(b)
▶$8.3MraisedNov 2019 · 14 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Luk VandenbergheDirector
- Rick ModiExecutive Officer
- Offering amount
- $8.3M
- Amount sold
- $8.3M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapIQVIA10 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Bioworld10 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Affinia Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Affinia Therapeutics do?
- Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions. The company uses AI and structural modeling to redesign viral delivery vectors for one-time-dose genetic medicines across rare and prevalent diseases.
- Who founded Affinia Therapeutics?
- Affinia Therapeutics was founded by Luc Vandenberghe in 2019.
- Who are Affinia Therapeutics's investors?
- Affinia Therapeutics's investors include Atlas Venture, EcoR1 Capital, Eight Roads Ventures, F-Prime Capital, GV (Google Ventures), New Enterprise Associates (NEA), TCG Crossover, NEA Secondary.
- How much funding has Affinia Therapeutics raised?
- Affinia Therapeutics has disclosed $170.1M raised across 4 rounds.
- Where is Affinia Therapeutics headquartered?
- Affinia Therapeutics is headquartered in Waltham, US.